Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

NCT01481545 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

RADIATION: Radiation therapy
DRUG: Oxaliplatin
DRUG: Raltitrexed
DRUG: levofolinic acid
DRUG: 5-fluorouracil
DRUG: Bevacizumab

Sponsor

National Cancer Institute, Naples